HomepageAUROPHARMA • NSE
add
Aurobindo Pharma
Vorige slotkoers
₹ 1.231,90
Dag-range
₹ 1.182,10 - ₹ 1.250,00
Jaar-range
₹ 1.010,00 - ₹ 1.278,60
Beurswaarde
724,38Â mld. INR
Gem. volume
1,98Â mln.
Koers/winst
20,78
Dividendrendement
0,32%
Primaire beurs
NSE
Marktnieuws
Financiële informatie
Resultatenrekening
Opbrengst
Netto inkomsten
| (INR) | dec 2025info | Wijziging j-o-j |
|---|---|---|
Opbrengst | 86,46Â mld. | 8,36% |
Bedrijfskosten | 38,56Â mld. | 11,65% |
Netto inkomsten | 9,10Â mld. | 7,62% |
Netto winstmarge | 10,53 | -0,66% |
Winst per aandeel | 16,43 | 12,87% |
EBITDA | 16,71Â mld. | 7,63% |
Effectief belastingtarief | 32,03% | — |
Balans
Totale activa
Totale passiva
| (INR) | dec 2025info | Wijziging j-o-j |
|---|---|---|
Contanten en kortetermijnbeleggingen | 88,92Â mld. | 29,47% |
Totale activa | — | — |
Totale passiva | — | — |
Totaal aandelenvermogen | 350,34 mld. | — |
Uitstaande aandelen | 580,91 mln. | — |
Koers-boekwaardeverhouding | 2,04 | — |
Rendement op activa | — | — |
Rendement op kapitaal | 7,64% | — |
Kasstroom
Nettomutatie in liquide middelen
| (INR) | dec 2025info | Wijziging j-o-j |
|---|---|---|
Netto inkomsten | 9,10Â mld. | 7,62% |
Operationele kasstroom | — | — |
Kasstroom uit beleggingen | — | — |
Kasstroom uit financiering | — | — |
Nettomutatie in liquide middelen | — | — |
Vrije kasstroom | — | — |
Over
Aurobindo Pharma Limited is an Indian multinational pharmaceutical manufacturing company based in HITEC City, Hyderabad, with U.S. headquarters in East Windsor, Mercer County, New Jersey. The company manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company's area of activity includes six major therapeutic and product areas: antibiotics, anti-retrovirals, cardiovascular products, central nervous system products, gastroenterologicals, and anti-allergics. The company markets these products in over 125 countries. Its marketing partners include Pfizer and AstraZeneca. Wikipedia
Opgericht
1986
Hoofdvestiging
Website
Werknemers
27.707
